Biocracked
Approach 3, the human outcome, in palette C, natural.

Low-angle side view of an older adult's lower legs and walking shoes mid-stride on a long outdoor paved path in a park, shot with a shallow depth of field. The face is out of frame. Late-morning daylight filters through green trees and casts dappled light across weathered skin, worn grey sneakers and the pavement. Two faint chalk-white distance marks on the path sit in soft focus ahead, suggesting a measured walk test. Plant greens, warm earth-brown soil edges and natural skin tones dominate, with a tiny electric green detail on the shoe's lace tip. The mood is calm, honest and measured, hopeful but cautious, and the image feels like documentary photography with crisp texture and no staged gloss.
Supplements

Urolithin A for Muscle: What 5 Human Trials Actually Show

Dr. Synapse · · 4 min read

If you've seen an ad for Mitopure or another urolithin A supplement, you've probably been told it "recycles your mitochondria" and helps muscles stay young. The mechanism is real biology. But a new systematic review and meta-analysis pooled every randomized human trial it could find, and the answer to "does it actually improve muscle performance?" is more modest: possibly, but nobody can say yet.

The review, published in Frontiers in Nutrition in 2026 by Dao and colleagues, is the first to gather the randomized controlled trial (RCT) evidence on urolithin A and muscle health. Here is what it found and what that means if you're deciding whether to buy.

What Is Urolithin A?

Urolithin A (UA) isn't something you eat directly. It's a metabolite made by certain gut bacteria from ellagitannins and ellagic acid, polyphenols found in pomegranates, walnuts, some berries, and oak-aged foods. Whether you produce meaningful UA from those foods depends on your microbiome. Some people convert ellagitannins to UA efficiently, and many convert them poorly or not at all. That variability is the commercial case for taking UA directly as a supplement.

The scientific interest centers on mitophagy, the cellular housekeeping process that clears out damaged mitochondria. Mitochondrial quality tends to decline with age, and skeletal muscle is energy-hungry tissue. In animal and cell models, UA appears to stimulate mitophagy and improve muscle function. The hypothesis that it could do the same in people is reasonable. It is still a hypothesis.

What the Meta-Analysis Found

The authors searched PubMed, Embase, Web of Science, and Scopus through December 2025 for RCTs comparing oral UA with placebo and reporting muscle-related outcomes. They found only five trials with 236 participants in total. Those trials differed in population, dose, duration, and outcome measures.

That heterogeneity limited what could be combined statistically. Only one outcome, the 6-minute walk test (6MWT), could be pooled, and only from two trials. The results:

  • Pooled mean difference: +17.03 meters in favor of UA
  • 95% confidence interval: -5.33 to +39.40 m
  • p-value: 0.135, not statistically significant
  • Sensitivity analysis (splitting the placebo group instead of combining arms): +18.80 m, 95% CI -3.24 to 40.85, p = 0.095, similar
  • GRADE certainty: low

The confidence interval is the key detail. It spans a small decline in walking distance to a fairly meaningful gain. The data are consistent with UA doing nothing, and also with it helping moderately. A 17-meter improvement sounds encouraging, but the study can't distinguish it from chance.

The authors also note that the 500 mg and 1,000 mg arms from one trial were combined against a shared placebo group, following Cochrane guidance, to avoid counting placebo participants twice. That is the statistically correct way to do it, but it means the pooled figure blends two doses.

What About Strength, Endurance, and Mitochondrial Markers?

Muscle strength, endurance, aerobic capacity, and biochemical or mitochondrial biomarkers were reviewed narratively, not pooled. The authors describe these findings as "exploratory signals rather than reproducible effects." Some individual trials reported favorable changes, but the populations, doses, and measurement methods varied too much to confirm a consistent benefit. Marketing often cites these individual positive findings, and the meta-analysis explicitly declines to treat them as proof.

Why the Evidence Is Thin

Several problems stack up:

  1. Small samples. 236 people across five trials is little data for a supplement marketed so widely.
  2. Short duration. The trials were short-term. Muscle aging unfolds over years, and the studies can't show whether UA changes that trajectory.
  3. Mixed populations. The participants were clinically heterogeneous, so a result in one group (say, older sedentary adults) may not apply to another (say, trained athletes).
  4. Inconsistent outcomes. Without standardized endpoints, trials can't be compared or pooled, so scattered positive results can't be turned into a firm conclusion.
  5. Surrogate markers. Changes in mitochondrial biomarkers don't necessarily mean better muscle function in daily life.

The authors' conclusion is plain: larger, longer, standardized trials in better-defined populations are needed before firm clinical recommendations can be made. Notably, they declared no commercial conflicts of interest, which matters in a field where much of the research is industry-linked.

Practical Takeaways

Doses in the trials. The studies discussed used 500 mg and 1,000 mg per day. If you try UA, those are the doses with human trial data behind them. There's no evidence that going higher helps.

Who might still consider it. Older adults with declining mobility, or people with low dietary ellagitannin intake who want to experiment, are the groups with the most plausible upside. The 6MWT signal points in that direction. The safety profile in the trials appears reasonable, but this review focused on efficacy, so check the individual trials and talk to your clinician, especially if you take medications or have a medical condition.

What to expect. Don't expect a dramatic change in muscle size or strength. The best-case scenario from current data is a modest improvement in walking endurance after months of consistent use, and even that isn't confirmed.

Cost-benefit. Branded UA supplements are premium-priced, often far more than established, better-evidenced options. If your budget is limited, resistance training, adequate protein, sleep, and regular aerobic activity have much stronger evidence for preserving muscle and mitochondrial function. UA is a possible add-on at best, not a substitute. If you're curious, treat it as a low-certainty experiment: set a baseline (walk test, grip strength, or a simple lift), try it for 3 to 4 months, and judge by objective measures, not by how you feel.

The Bottom Line

Urolithin A is a scientifically interesting compound with a plausible mechanism and a promising but unproven human track record for muscle. The most rigorous summary so far shows a directionally positive but statistically inconclusive effect on one walking outcome, with low-certainty evidence behind it. That isn't "it doesn't work," and it isn't "it's proven." It is "we don't know yet," and anyone selling certainty is ahead of the data.

Original study

Read the original research on pubmed.ncbi.nlm.nih.gov →

This article summarizes published research for general information. It is not medical advice.

DS

Written by

Dr. Synapse

Dr. Synapse writes for Biocracked: biohacking science, longevity & human performance.

Related Articles

Approach 4, conceptual metaphor, in palette D, bold color field.

A single translucent green tea leaf, its veins backlit, lies on a saturated magenta seamless backdrop beside a small pomegranate rind fragment. Together they form a split, two-part chain: a bright brass chain link made of two interlocking rings, one ring dark amber and one pale green, rests on top. Behind it, one ring has a hairline crack. Shot from a low three-quarter angle with a shallow depth of field, the front link razor sharp and the background softly blurred. Lighting is a crisp, hard key light from the upper left with a soft magenta bounce and a long defined shadow across the surface. The palette is vivid magenta, deep amber, and a small accent of electric green (#00e676) on the leaf edge. The mood is curious and skeptical: promising but unproven, with two parts joined yet not fully tested.
longevity

Urolithin A + Green Tea EGCG in Alzheimer's Mice: The Catch

BY NOVA CHEN ·

Two natural compounds, urolithin A and green tea's EGCG, were given together to Alzheimer's-model mice, and the animals' mitochondria looked markedly different afterward. Treated mice showed shifts in fission and fusion genes, higher mitophagy-associated markers, longer mitochondria and more ATP. The combination often outperformed the regimen without EGCG across mitochondrial and neuronal measures. But this was injected dosing in mice, and the authors say mitophagic flux, respiration and EGCG's specific role still need testing. Here's what the study found, what it can't tell us, and why it isn't a supplement recommendation.

**Approach:** Conceptual metaphor, in a bold color field palette (D).

A single ripe pomegranate, split open, on a saturated teal backdrop. It is the natural source of urolithin A's precursors. The camera sits at a slightly low three-quarter angle, close enough to show glossy, translucent arils. On the left half, the arils sit dull and tightly packed. On the right, a few arils hold a faint electric green glow, as if lit from within, hinting at a selective response in one place and not another. Behind the fruit, a thin copper wire runs across the frame and is unbroken on one side and fraying on the other, standing for arteries versus brain vessels. Soft, directional studio light from the upper left casts crisp shadows. Mood: curious, restrained, quietly hopeful. No text anywhere.
supplements

Urolithin A Didn't Fix Arteries in 4 Weeks, but the Brain Responded

BY NOVA CHEN ·

A double-blind trial of 50 adults aged 40-64 with obesity found that 1,000 mg of urolithin A daily for four weeks did not improve flow-mediated dilation, the study's primary endpoint. Peripheral microvascular measures were also unchanged. Yet task-evoked cerebrovascular hemodynamic responses were significantly greater with urolithin A than with placebo, even though task performance did not budge. Because the brain result is a secondary outcome from a short, small trial, it is a lead rather than a conclusion. Here is what the data show, what they don't, and what it means for anyone considering the supplement.

Approach: Macro science. Palette: D, bold color field.

Extreme macro photograph of a single human T cell shown as a slightly bumpy, matte-textured sphere with fine microvilli, resting on a surface of smaller, out-of-focus cells. A faint electric green (#00e676) glow shows through a few lipid droplets inside its translucent membrane, hinting at fat-burning. The backdrop is a saturated magenta-violet field that fades from deep plum at the edges to bright magenta behind the cell. The camera sits at a low three-quarter angle with very shallow depth of field, so the foreground cell is crisp and the background melts into soft bokeh. Lighting is a soft, directional key from upper left with a thin rim light that picks out the membrane texture. The look is scanning-electron-microscope realism with subtle color, not cartoon. The mood is curious, quietly skeptical and precise. There is no text and no labels. The composition leaves open space on the right.
longevity

Urolithin A Shifted Aging T Cells in 4 Weeks. Here's the Catch

BY NOVA CHEN ·

A randomized trial in Nature Aging found that four weeks of urolithin A shifted the immune profile of healthy middle-aged adults. It expanded naive-like CD8+ T cells and boosted their fat-burning capacity. But the headline number is small: a 0.5 percentage point change. The study ran only 4 weeks in 50 people, measured biomarkers rather than infections, and was funded by the maker of Mitopure. Here is what the data show, what they don't, and who might want to pay attention.

A wide, softly lit editorial still life on a pale travertine surface. In the center-left, a halved ruby-red pomegranate sits open, its glossy arils spilling in a loose cluster onto the stone. Beside it are a few cracked walnut halves and a small matte ceramic dish holding a pinch of fine cream-colored powder. A single aril catches a bright highlight near the foreground. In the soft-focus background, a sheer linen curtain filters warm morning sunlight, which casts long, gentle shadows across the scene.

On the right side, an elegant older woman's hand, seen only from the wrist down, rests lightly on the surface next to a minimalist glass of water. Her skin shows natural texture and warmth. A slim sprig of dried olive branch and a folded sage-green napkin add quiet, organic accents.

The palette is restrained and modern: deep garnet red, warm walnut brown, oat beige, soft sage, and creamy off-white. The composition leaves generous negative space on the upper right for title text. The depth of field is shallow, with crisp focus on the pomegranate and a creamy bokeh falloff. The lighting is natural, diffused, and slightly golden, in the style of a high-end wellness magazine or a contemporary science and nutrition journal. The mood is calm, clean, and quietly authoritative. The finish is photographic, with fine grain, subtle matte tones, and a premium editorial feel.
supplements

Urolithin A, the Pomegranate Postbiotic, Triggers a Mitophagy Signature in Older Adults

BY DR. SYNAPSE ·

Urolithin A, a molecule made by gut bacteria from pomegranate and walnut polyphenols, has long rejuvenated muscle in aging animals. The first human trial in older adults found it safe, bioavailable, and able to shift mitochondrial biomarkers at 500 to 1,000 mg a day. The study, backed by the company behind Mitopure, showed a molecular signature of improved mitochondrial health in muscle. But it was small, short, and measured biomarkers rather than strength or longevity. Here is what the data show, who it is aimed at, and where the evidence stops.

This page is available in